<DOC>
	<DOCNO>NCT02333526</DOCNO>
	<brief_summary>The aim study evaluate soluble biomarker syndecan-1 ( sSdc1 ) take venous blood patient infectious intestinal disease Clostridium difficile-associated colitis , bacterial colitis , Norovirus enteritis CrohnÂ´s disease ulcerative colitis . The level sSdc1 compare disease activity patient active inflammation disease remission . Secondary objective assessment correlation above-mentioned factor CRP value . Subjects volunteer . Blood take part routine clinical work-up write agreement blood sSdc1-level assess use human-specific sSdc1 ELISA assay . In addition , subject ask answer short questionnaire . The study design prospective , comparative cohort study .</brief_summary>
	<brief_title>Syndecan 1 Biomarker Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Subject least 18 year age able give inform consent healthy volunteer inflammatory bowel condition ( inflammatory bowel disease , infectious colitis ) able give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>Clostidium difficile-associated colitis</keyword>
	<keyword>Syndecan-1</keyword>
	<keyword>biomarker</keyword>
</DOC>